CA2241981A1 - Method of inhibiting photoaging of skin - Google Patents
Method of inhibiting photoaging of skinInfo
- Publication number
- CA2241981A1 CA2241981A1 CA002241981A CA2241981A CA2241981A1 CA 2241981 A1 CA2241981 A1 CA 2241981A1 CA 002241981 A CA002241981 A CA 002241981A CA 2241981 A CA2241981 A CA 2241981A CA 2241981 A1 CA2241981 A1 CA 2241981A1
- Authority
- CA
- Canada
- Prior art keywords
- skin
- photoaging
- exposure
- uvb irradiation
- administering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010051246 Photodermatosis Diseases 0.000 title abstract 2
- 230000008845 photoaging Effects 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title 1
- 102000030782 GTP binding Human genes 0.000 abstract 1
- 108091000058 GTP-Binding Proteins 0.000 abstract 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 abstract 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/58—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Abstract
Photoaging of undamaged skin due to UVB irradiation exposure is inhibited by administering an agent that inhibits at least one of (1) the activity of UVB irradiation inducible MMPs in the skin, (2) one or both of the transcription factors AP-1 and NF-.lambda.B or (3) at least one of the GTP binding proteins or kinases involved in the activation and/or production of jun or fos proteins that comprise AP-1; and topically administering said inhibitor to the skin prior to such exposure.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/588,771 | 1996-01-19 | ||
US08/588,771 US5837224A (en) | 1996-01-19 | 1996-01-19 | Method of inhibiting photoaging of skin |
PCT/US1997/000791 WO1997025969A1 (en) | 1996-01-19 | 1997-01-17 | Method of inhibiting photoaging of skin |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2241981A1 true CA2241981A1 (en) | 1997-07-24 |
CA2241981C CA2241981C (en) | 2002-03-19 |
Family
ID=24355242
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002241981A Expired - Lifetime CA2241981C (en) | 1996-01-19 | 1997-01-17 | Method of inhibiting photoaging of skin |
Country Status (21)
Country | Link |
---|---|
US (1) | US5837224A (en) |
EP (1) | EP0883398A4 (en) |
JP (1) | JP3705820B2 (en) |
CN (1) | CN1086937C (en) |
AR (1) | AR005650A1 (en) |
BR (1) | BR9707018A (en) |
CA (1) | CA2241981C (en) |
CO (1) | CO4770951A1 (en) |
CZ (1) | CZ291530B6 (en) |
EE (1) | EE9800216A (en) |
HK (1) | HK1018885A1 (en) |
HU (1) | HUP9900655A3 (en) |
LT (1) | LT4515B (en) |
MY (1) | MY119711A (en) |
NO (1) | NO983019L (en) |
NZ (1) | NZ330860A (en) |
PL (1) | PL327827A1 (en) |
SI (1) | SI9720015A (en) |
SK (1) | SK95998A3 (en) |
TR (1) | TR199801376T2 (en) |
WO (1) | WO1997025969A1 (en) |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6528483B2 (en) | 1995-06-07 | 2003-03-04 | André Beaulieu | Method of producing concentrated non-buffered solutions of fibronectin |
WO1997020824A1 (en) * | 1995-12-08 | 1997-06-12 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation |
US6500948B1 (en) | 1995-12-08 | 2002-12-31 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof |
US5837224A (en) * | 1996-01-19 | 1998-11-17 | The Regents Of The University Of Michigan | Method of inhibiting photoaging of skin |
US6008243A (en) * | 1996-10-24 | 1999-12-28 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use |
US6174915B1 (en) | 1997-03-25 | 2001-01-16 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
CA2281944C (en) * | 1997-02-25 | 2007-05-15 | The Regents Of The University Of Michigan | Methods and compositions for preventing and treating chronological aging in human skin |
US5985900A (en) * | 1997-04-01 | 1999-11-16 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
US20050058709A1 (en) * | 1997-06-04 | 2005-03-17 | Fisher Gary J. | Methods for inhibiting photoaging of human skin using orally-administered agent |
TWI234467B (en) * | 1997-06-04 | 2005-06-21 | Univ Michigan | Composition for inhibiting photoaging of skin |
JP3973748B2 (en) * | 1998-01-14 | 2007-09-12 | 花王株式会社 | Hair growth inhibitor |
US6683069B1 (en) * | 1998-04-02 | 2004-01-27 | Regents Of The University Of Michigan | Methods and compositions for reducing UV-induced inhibition of collagen synthesis in human skin |
FR2777186B1 (en) * | 1998-04-10 | 2001-03-09 | Oreal | USE OF AT LEAST ONE HYDROXYSTILBENE IN A FIRMING COMPOSITION |
FR2777183B1 (en) * | 1998-04-10 | 2001-03-02 | Oreal | USE OF AT LEAST ONE HYDROXYSTILBENE IN A COMPOSITION FOR PROMOTING DEQUAMATION OF THE SKIN AND COMPOSITION COMPRISING SAME |
US20060212025A1 (en) | 1998-11-30 | 2006-09-21 | Light Bioscience, Llc | Method and apparatus for acne treatment |
US6283956B1 (en) * | 1998-11-30 | 2001-09-04 | David H. McDaniels | Reduction, elimination, or stimulation of hair growth |
US6887260B1 (en) | 1998-11-30 | 2005-05-03 | Light Bioscience, Llc | Method and apparatus for acne treatment |
US9192780B2 (en) | 1998-11-30 | 2015-11-24 | L'oreal | Low intensity light therapy for treatment of retinal, macular, and visual pathway disorders |
US6071955A (en) * | 1999-02-25 | 2000-06-06 | The Regents Of The University Of California | FXR, PPARA and LXRA activators to treat acne/acneiform conditions |
WO2000051562A1 (en) * | 1999-03-03 | 2000-09-08 | Shiseido Company, Ltd. | Matrix metalloprotease inhibitor and utilization thereof |
AU4064100A (en) * | 1999-04-01 | 2000-10-23 | Board Of Trustees Of The University Of Arkansas, The | P38mapk inhibitor and uses thereof |
US7268148B2 (en) * | 1999-05-20 | 2007-09-11 | Regents Of The University Of Michigan | Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes |
US20040235950A1 (en) * | 1999-05-20 | 2004-11-25 | Voorhees John J. | Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes |
JP2003504415A (en) * | 1999-07-20 | 2003-02-04 | メルク エンド カムパニー インコーポレーテッド | Sustained-release drug dispersant delivery device |
US6982284B1 (en) | 1999-09-10 | 2006-01-03 | Applied Genetics Incorporated Dermatics | Compositions and methods for modification of skin lipid content |
DE19955349A1 (en) * | 1999-11-17 | 2001-08-02 | Switch Biotech Ag | Use of novel polypeptide or its variant or nucleic acid encoding the polypeptide for diagnosing and/or preventing and/or treating skin disorders and/or treatment in wound healing or for identifying active substances |
JP4074043B2 (en) * | 2000-03-27 | 2008-04-09 | 株式会社資生堂 | Skin basement membrane formation promoter, artificial skin formation promoter, and method for producing artificial skin |
DE10020447A1 (en) * | 2000-03-31 | 2001-10-11 | Henkel Kgaa | Use of protease inhibitors in cosmetics and pharmacy |
AU2001272028A1 (en) * | 2000-06-26 | 2002-01-08 | The Regents Of The University Of Michigan | Use of egf-r protein tyrosine kinase inhibitors for preventing photoaging in human skin |
US20040185127A1 (en) * | 2001-06-29 | 2004-09-23 | Lerner David S. | Cosmetic composition and method |
AU2001273115C1 (en) * | 2000-06-29 | 2009-03-26 | Quick Med Technologies, Inc. | Cosmetic composition and method |
WO2002003940A2 (en) | 2000-07-06 | 2002-01-17 | The Regents Of The University Of Michigan | Uva (>360-400) and uvb (300-325) specific sunscreens |
FR2811563B1 (en) * | 2000-07-13 | 2003-06-20 | Oreal | COMPOSITION, ESPECIALLY COSMETIC, COMPRISING DHEA AND / OR A PRECURSOR OR DERIVATIVE, AND AT LEAST ONE COMPOUND INCREASING THE SYNTHESIS OF GLYCOSAMINOGLYCANS |
FR2811561B1 (en) * | 2000-07-13 | 2003-03-21 | Oreal | COMPOSITION, ESPECIALLY COSMETIC, CONTAINING DHEA AND / OR A CHEMICAL OR BIOLOGICAL PRECURSOR OR DERIVATIVE THEREOF, AND A METALLOPROTEINASE INHIBITOR |
US20020119107A1 (en) * | 2000-12-18 | 2002-08-29 | James Varani | Method for protecting and restoring skin using selective MMP inhibitors |
DE10102784A1 (en) * | 2001-01-22 | 2002-08-01 | Henkel Kgaa | Cosmetic or pharmaceutical preparations for the treatment of epithelial cover tissue |
JP2002277455A (en) * | 2001-03-15 | 2002-09-25 | Shiseido Co Ltd | Composition and method for detecting skin aging gene |
KR101210018B1 (en) | 2002-03-08 | 2012-12-07 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | Macrocyclic compounds useful as pharmaceutical |
US7354956B2 (en) * | 2002-04-12 | 2008-04-08 | L'oreal | Composition containing a sapogenin and use thereof |
AU2003225161A1 (en) * | 2002-04-24 | 2003-11-10 | Koo, Han-Mo | Enhancement of human epidermal melanogenesis |
CN101601702B (en) | 2002-06-25 | 2012-04-18 | 株式会社资生堂 | Anti-aging agent |
US7521584B2 (en) * | 2002-07-29 | 2009-04-21 | Cardax Pharmaceuticals, Inc. | Carotenoid analogs or derivatives for the inhibition and amelioration of disease |
US7763649B2 (en) * | 2002-07-29 | 2010-07-27 | Cardax Pharmaceuticals, Inc. | Carotenoid analogs or derivatives for controlling connexin 43 expression |
US20050004235A1 (en) * | 2002-07-29 | 2005-01-06 | Lockwood Samuel Fournier | Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease |
US7345091B2 (en) * | 2002-07-29 | 2008-03-18 | Cardax Pharmaceuticals, Inc. | Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease |
US20050148517A1 (en) * | 2002-07-29 | 2005-07-07 | Lockwood Samuel F. | Carotenoid ether analogs or derivatives for controlling connexin 43 expression |
US7320997B2 (en) * | 2002-07-29 | 2008-01-22 | Cardax Pharmaceuticals, Inc. | Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease |
US20050009788A1 (en) * | 2002-07-29 | 2005-01-13 | Lockwood Samuel Fournier | Carotenoid ester analogs or derivatives for controlling connexin 43 expression |
US20050059635A1 (en) * | 2002-07-29 | 2005-03-17 | Lockwood Samuel Fournier | Carotenoid ester analogs or derivatives for controlling C-reactive protein levels |
US20050026874A1 (en) * | 2002-07-29 | 2005-02-03 | Lockwood Samuel Fournier | Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease |
US20050143475A1 (en) * | 2002-07-29 | 2005-06-30 | Lockwood Samuel F. | Carotenoid analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury |
US7723327B2 (en) * | 2002-07-29 | 2010-05-25 | Cardax Pharmaceuticals, Inc. | Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease |
US7375133B2 (en) * | 2002-07-29 | 2008-05-20 | Cardax Pharmaceuticals, Inc. | Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease |
MXPA05001202A (en) * | 2002-07-29 | 2005-11-23 | Hawaii Biotech Inc | Structural carotenoid analogs for the inhibition and amelioration of disease. |
US20050049248A1 (en) * | 2002-07-29 | 2005-03-03 | Lockwood Samuel Fournier | Carotenoid ether analogs or derivatives for controlling C-reactive protein levels |
US20050059659A1 (en) * | 2002-07-29 | 2005-03-17 | Lockwood Samuel Fournier | Carotenoid analogs or derivatives for controlling C-reactive protein levels |
CA2531099A1 (en) | 2003-04-10 | 2004-10-28 | Light Bioscience, Llc | Photomodulation methods and devices for regulating cell proliferation and gene expression |
CA2533129A1 (en) * | 2003-07-31 | 2005-02-10 | Light Bioscience, Llc | System and method for the photodynamic treatment of burns, wounds, and related skin disorders |
FR2858932B1 (en) * | 2003-08-22 | 2009-10-30 | Oreal | COMPOSITION FOR CONTROLLING THE DEGRADATION OF INDUCED COLLAGEN FIBERS IN NATURAL SOLAR EXPOSURE CONDITIONS |
US20050058611A1 (en) * | 2003-08-22 | 2005-03-17 | L'oreal | Preventing and/or combating collagen fiber degradation induced under conditions of natural exposure to sunlight |
EP1730522A2 (en) * | 2004-03-29 | 2006-12-13 | Howard Murad | Methods for treating dermatological conditions in a patient |
EP1750723A1 (en) * | 2004-04-14 | 2007-02-14 | Hawaii Biotech, Inc. | Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation |
US20060058269A1 (en) * | 2004-04-14 | 2006-03-16 | Lockwood Samuel F | Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation |
US8338648B2 (en) * | 2004-06-12 | 2012-12-25 | Signum Biosciences, Inc. | Topical compositions and methods for epithelial-related conditions |
US20060265030A1 (en) * | 2004-11-12 | 2006-11-23 | Light Bioscience, Llc | System and method for photodynamic cell therapy |
EP1824336A4 (en) * | 2004-12-02 | 2009-10-14 | Univ North Carolina | Inhibition of hsp27 phosphorylation for treatment of blistering disorders |
US20090069638A1 (en) * | 2005-12-02 | 2009-03-12 | Howard Murad | Diagnostic and Treatment Regimen for Achieving Body Water Homeostasis |
US8771647B2 (en) * | 2005-12-20 | 2014-07-08 | Kao Corporation | Human photoaged skin model |
US7642402B2 (en) * | 2005-12-20 | 2010-01-05 | Kao Corporation | Human photoaged skin model |
US20090220436A1 (en) * | 2006-05-11 | 2009-09-03 | Living Proof, Inc. | In situ polymerization for skin treatment |
KR100879558B1 (en) * | 2007-07-31 | 2009-01-22 | 라이브켐 주식회사 | Compositions for skin protection and improvement of skin diseases containing the dibenzo-p-dioxine derivatives |
CA2757342C (en) * | 2008-04-01 | 2017-05-09 | Biopharmacopae Design International Inc. | Extracts from plants of the tsuga genus and uses thereof in the treatment of inflammation, irritation and/or infection |
US20110038853A1 (en) * | 2008-04-22 | 2011-02-17 | Centre National De La Recherche Scientifique | Use of Kif13A and AP-1 Inhibitors for Inhibiting Melanogenesis |
EP2484349B1 (en) | 2009-09-30 | 2014-04-02 | Shiseido Co., Ltd. | 4-isobutylresorcinol, as heparanase-activity inhibitor, for preventing or suppressing the formation of wrinkles |
US8609075B2 (en) | 2009-09-30 | 2013-12-17 | Shiseido Company, Ltd. | Heparanase activity inhibitor |
US8435541B2 (en) | 2010-09-02 | 2013-05-07 | Bath & Body Works Brand Management, Inc. | Topical compositions for inhibiting matrix metalloproteases and providing antioxidative activities |
US10267796B2 (en) * | 2010-10-25 | 2019-04-23 | The Procter & Gamble Company | Screening methods of modulating adrenergic receptor gene expressions implicated in melanogenesis |
EP2934555B1 (en) | 2012-12-21 | 2021-09-22 | Astellas Institute for Regenerative Medicine | Methods for production of platelets from pluripotent stem cells |
JP2015221768A (en) * | 2014-05-23 | 2015-12-10 | 日本メナード化粧品株式会社 | External or internal preparation for skin |
JP2016216435A (en) * | 2015-05-18 | 2016-12-22 | 共栄化学工業株式会社 | Evaluation method |
JP6157659B1 (en) * | 2016-02-10 | 2017-07-05 | イノレックス インベストメント コーポレイション | Synergistic compositions, formulations and related methods for reducing UV-induced lipid peroxidation |
US9943566B2 (en) | 2016-03-16 | 2018-04-17 | Geoffrey Brooks Consultants, Llc | NF-κB inhibitor composition for skin health |
CN112263529A (en) * | 2020-10-27 | 2021-01-26 | 圣菲之美(湖北)生物科技有限公司 | Anti-aging composition and preparation method and application thereof |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4603146A (en) * | 1984-05-16 | 1986-07-29 | Kligman Albert M | Methods for retarding the effects of aging of the skin |
US4877805A (en) * | 1985-07-26 | 1989-10-31 | Kligman Albert M | Methods for treatment of sundamaged human skin with retinoids |
US5019569A (en) * | 1986-11-03 | 1991-05-28 | Ortho Pharmaceutical Corporation | Reversal of glucocorticoid-induced skin atrophy |
AU610587B2 (en) * | 1987-04-06 | 1991-05-23 | Daltex Medical Sciences, Inc. | Treatment of aged skin with oral 13-cis-retinoic acid |
US4994491A (en) * | 1988-12-14 | 1991-02-19 | Molecular Design International | Dermal uses of trans-retinoids for the treatment of cancer |
AU636595B2 (en) * | 1989-01-19 | 1993-05-06 | Ortho Pharmaceutical Corporation | Method for the treatment or prevention of intrinsically aged skin with retinoids |
US5002760A (en) * | 1989-10-02 | 1991-03-26 | Katzev Phillip K | Retinol skin care composition |
US5051449A (en) * | 1991-02-27 | 1991-09-24 | Kligman Albert M | Treatment of cellulite with retinoids |
EP0614353A1 (en) * | 1991-11-25 | 1994-09-14 | Richardson-Vicks, Inc. | Compositions for regulating skin wrinkles and/or skin atrophy |
GR1002207B (en) * | 1992-08-06 | 1996-03-27 | Johnson & Johnson Consumer | Skin care compositions containing imidazoles. |
EP0806947A4 (en) * | 1995-02-03 | 1998-10-14 | Cosmederm Technologies | Formulations and methods for reducing skin irritation |
DE69632255T3 (en) * | 1995-06-08 | 2010-05-20 | Johnson & Johnson Consumer Companies, Inc. | SUNSCREEN |
US5837224A (en) * | 1996-01-19 | 1998-11-17 | The Regents Of The University Of Michigan | Method of inhibiting photoaging of skin |
-
1996
- 1996-01-19 US US08/588,771 patent/US5837224A/en not_active Expired - Lifetime
-
1997
- 1997-01-17 CZ CZ19982258A patent/CZ291530B6/en not_active IP Right Cessation
- 1997-01-17 EE EE9800216A patent/EE9800216A/en unknown
- 1997-01-17 PL PL97327827A patent/PL327827A1/en unknown
- 1997-01-17 CO CO97001933A patent/CO4770951A1/en unknown
- 1997-01-17 HU HU9900655A patent/HUP9900655A3/en unknown
- 1997-01-17 JP JP52622497A patent/JP3705820B2/en not_active Expired - Fee Related
- 1997-01-17 SK SK959-98A patent/SK95998A3/en unknown
- 1997-01-17 CN CN97191735A patent/CN1086937C/en not_active Expired - Fee Related
- 1997-01-17 BR BR9707018A patent/BR9707018A/en not_active IP Right Cessation
- 1997-01-17 MY MYPI97000167A patent/MY119711A/en unknown
- 1997-01-17 TR TR1998/01376T patent/TR199801376T2/en unknown
- 1997-01-17 NZ NZ330860A patent/NZ330860A/en not_active IP Right Cessation
- 1997-01-17 AR ARP970100191A patent/AR005650A1/en unknown
- 1997-01-17 SI SI9720015A patent/SI9720015A/en unknown
- 1997-01-17 CA CA002241981A patent/CA2241981C/en not_active Expired - Lifetime
- 1997-01-17 WO PCT/US1997/000791 patent/WO1997025969A1/en active IP Right Grant
- 1997-01-17 EP EP97903847A patent/EP0883398A4/en not_active Withdrawn
-
1998
- 1998-06-29 NO NO983019A patent/NO983019L/en not_active Application Discontinuation
- 1998-07-09 LT LT98-091A patent/LT4515B/en not_active IP Right Cessation
-
1999
- 1999-09-14 HK HK99103976A patent/HK1018885A1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
JP3705820B2 (en) | 2005-10-12 |
SI9720015A (en) | 1999-10-31 |
JP2000503660A (en) | 2000-03-28 |
MY119711A (en) | 2005-07-29 |
TR199801376T2 (en) | 1998-10-21 |
SK95998A3 (en) | 1999-01-11 |
BR9707018A (en) | 1999-07-20 |
EE9800216A (en) | 1999-04-15 |
US5837224A (en) | 1998-11-17 |
AU1831797A (en) | 1997-08-11 |
HK1018885A1 (en) | 2000-01-07 |
AR005650A1 (en) | 1999-07-14 |
CZ291530B6 (en) | 2003-03-12 |
CZ225898A3 (en) | 1998-10-14 |
NO983019L (en) | 1998-08-19 |
NZ330860A (en) | 1999-11-29 |
WO1997025969A1 (en) | 1997-07-24 |
EP0883398A1 (en) | 1998-12-16 |
HUP9900655A1 (en) | 1999-07-28 |
AU701132B2 (en) | 1999-01-21 |
CO4770951A1 (en) | 1999-04-30 |
LT4515B (en) | 1999-06-25 |
PL327827A1 (en) | 1999-01-04 |
EP0883398A4 (en) | 1999-05-12 |
CA2241981C (en) | 2002-03-19 |
HUP9900655A3 (en) | 2000-09-28 |
CN1086937C (en) | 2002-07-03 |
LT98091A (en) | 1999-02-25 |
CN1211178A (en) | 1999-03-17 |
NO983019D0 (en) | 1998-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2241981A1 (en) | Method of inhibiting photoaging of skin | |
FI973492A (en) | NO synthase inhibitors | |
NL930005I2 (en) | 17 Beta-substituted-4-aza-5-alpha-androstenones and their use as inhibitors of 5-alpha-reduct ase. | |
DK0711140T3 (en) | Antimycotic solution for nails | |
NO954153D0 (en) | Electro-surgical processor, and method of use | |
BR9702541A (en) | Cosmetic and / or dermatological composition use of the composition and process for non-therapeutic cosmetic treatment | |
IE800102L (en) | N-benzylimidazoles | |
EE9900428A (en) | Anti-cough formulations | |
AU694702B2 (en) | W/O emulsion with a high electrolyte content, and its use in dermo-cosmetics, in particular for treating phenomena of irritation and/or of sensitive skin | |
CA2245206A1 (en) | Use of an inhibitor of excitatory amino acids in a cosmetic or dermatological compound for sensitive skin, and the compound thus obtained | |
WO1998018440A3 (en) | Use of inhibitors of the activity of retinoic acid for treating sensitive skin | |
EP0197358A3 (en) | Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of skin wrinkles and hyperpigmentation | |
IL138290A0 (en) | Use of selegiline or desmethylselegiline for treating wounds, burns and dermatological damage | |
AU4726797A (en) | Prophylactic/remedial agent | |
BG101126A (en) | The use of muramylpeptide compounds | |
DE69705110D1 (en) | TOPICAL PHARMACEUTICAL COMPOSITIONS CONTAINING HEPARIN | |
ATE234614T1 (en) | USE OF SELEGILINE TO TREAT HEARING LOSS IN MAMMALS | |
NO894008L (en) | WOOD PRESERVANT AND PROCEDURE FOR TREATMENT OF RETIREMENT WITH THE SAME. | |
EE9700350A (en) | New use of COMT inhibitors and a method for preventing diabetic vascular disorders | |
ES2139729T3 (en) | USE OF FACTOR XIII APPLIED TOPICALLY FOR THE INHIBITION OF BLEEDING. | |
BR9607612A (en) | Combination therapy of angiotensin converting enzyme inhibitor amount of reduced side effect of aldosterone antagonist and diuretic for the treatment of cardiovascular diseases | |
ES1034708Y (en) | PERFECTED ARRANGEMENT FOR THE COMPOSITION OF ATLAS AND SIMILAR, IN RELIEF. | |
ES1020960Y (en) | PERFECTED REMOVABLE BEAM, FOR CHANNELING OF CABLES IN OFFICE FURNITURE AND SIMILAR. | |
IT8324322A0 (en) | METHOD AND COMPOSITION FOR THE TOPICAL TREATMENT OF SOME SKIN DISEASE. | |
ES1027746Y (en) | PERFECTED UNION OF FLOOR AND LIFT IN FOOTWEAR. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20170117 |